Dear Editor-in-chief
====================

Rheumatoid Arthritis (RA) patients who are active smokers have high levels of Tumor Necrosis Factor (TNF) and a relatively higher ratio of TNF binding to soluble TNF receptor. Passive smoking may also impact the response of TNF treatment in patients with RA ([@B1]). The objective of this study was to assess the effect of tobacco smoke exposure, both through active and passive smoking, on response to anti-TNF-α agents at 12-month assessment.

In this study, patients with a diagnosis of RA under treatment with infliximab, etanercept and adalimubab therapy were retrospectively evaluated. Rheumatoid Factor (RF) positive patients undergoing a methotrexate (MTX) based anti-TNF treatments were enrolled. Patients were questioned whether they were active smokers or were passively exposed to tobacco smoke through a close contact. Outcome at 12 months was categorized according to the Disease Activity Score-28 (DAS28) scores using two approaches. First; non-responder (an improvement of \< 0.6 or have a final DAS28 score \> 5.1), moderate response and good response (an improvement of at least 1.2 units and achieves an absolute score of \< 3.2). Moderate responders were those that fall in between. Second; patients achieved remission at 12 months with DAS28 \< 2.6. Functional disability was determined using the Health Assessment Questionnaire (HAQ) ([@B2]).

Statistical analyses were performed using the SPSS, Chicago, IL, USA version 11.5. Yates' chi-squared and Fisher's exact tests were used to assess the differences within groups. Univariate analysis of variance test was used to determine the change within anti-TNFα groups in both DAS-28 and HAQ levels. A *P-*value \< 0.05 was considered as indicative of statistical significance.

The files of 81 RA patients were examined but only 39 patients could be included in the study. The demographic characteristics of the patients are presented in [Table 1](#T1){ref-type="table"}. The anti-TNF agents used by patients were infliximab (28%), etanercept (41%) and adalimumab (31%). The distribution of DAS-28 levels were statistically similar in patients with and without cigarette smoking (*P* = 0.987). Similar results were observed between the groups with and without exposure to smoking (*P* = 0.454).

###### 

Demographic features

  ----------------------------------------------------
  **Age (yr)**              **(mean ± SD) / n (%)**\
                            50.1 ± 13.7
  ------------------------- --------------------------
  Sex                       

  Female                    29 (74.4)

  Male                      10 (25.6)

  Education (year)          5.9 ± 3.2

  Disease duration (year)   16.9 ± 9.6

  Somoker                   10 (25)

  Non-smoker                29 (75)

  Exposure                  23 (59)

  Non-exposure              16 (41)
  ----------------------------------------------------

Among active smokers, 50% were determined as good responders and 20% as non-responders at the end of the 12 months. Among non-smokers, 76% were good responders, and only 3% were non-responders. Similar results were observed when comparing patients with and without exposure to smoking (with exposure; good response: 60%, non-response: 9%, and without exposure; good response: 82%, non-response: 6%). The effect of smoking on DAS-28 and HAQ levels at the end of the 12 months is demonstrated in [Table 2](#T2){ref-type="table"}.

###### 

Effect of smoking on DAS-28 and HAQ levels

             **Smoker (mean ± SD)**   ***P***   **Non-smoker (mean ± SD)**   ***P***   ***P***
  ---------- ------------------------ --------- ---------------------------- --------- ---------
  DAS-28     6.1 ± 0.6                          6.4 ± 0.9                              
  0.month                             0.01                                   0.00      0.41
  DAS-28     4.2 ± 1.6                          4.1 ± 1.4                              
  12.month                                                                             
  HAQ        1.6 ± 0.4                          1.7 ± 0.6                              
  0.month                             0.01                                   0.00      0.86
  HAQ        1 ± 0.9                            1.1 ± 0.7                              
  12.month                                                                             

Smoking was a negative prognostic factor for both MTX and anti-TNF treatment response ([@B3]). Moreover, a correlation between smoking and disease activity at start of anti-TNF treatment could not be demonstrated ([@B4]). The prevalence and effect on disease activity of having had second-hand exposure to tobacco smoke was analyzed in RA patients who had never smoked ([@B5]). No differences were found between patients who had never smoked and who had been exposed or had not been exposed second-hand to tobacco smoke. Similarly, in this study, patients with RA who had been exposed or had not been exposed to tobacco smoke showed a statistically significant decrease in the level of DAS-28 as well as the HAQ scores compared to baseline and end of the 12 month. In contrast to previous reports, no association between cigarette smoking or tobacco smoke exposure and poor response to anti-TNF treatment was found ([@B6]).

In summary, findings show that no difference was detected between active smokers, exposed to tobacco smoke, and non-smokers in terms of response to anti-TNF treatment in RA. Prospective controlled studies that include exposed to tobacco smoke are required to better define the response to anti-TNF-α agents.
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